Clinical Trials

200 enrolled 27 charts

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT07428018 2026-03-05

VIOLET

150 enrolled

Breast Neoplasms

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8

NCT07410559 2026-02-18

Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer

189 enrolled

Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

ER-Positive Breast Cancer

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Breast Neoplasms, Male

NCT07292207 2025-12-18

ARCHE

30 enrolled

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

162 enrolled

Breast Cancer Metastatic

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

26 enrolled

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

42 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT04305834 2025-09-24

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Breast Neoplasms

NCT06365788 2025-09-04

ABBICAR

53 enrolled

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT04227327 2025-07-29

HERMIONE-7

31 enrolled

Advanced Breast Cancer

NCT04352777 2025-07-20

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

18 enrolled

Breast Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Breast Neoplasms

NCT04523857 2025-04-04

ABBY

66 enrolled

Breast Neoplasms

NCT06259929 2025-02-18

Neo-AGILE

51 enrolled

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

29 enrolled

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

4 enrolled 7 charts

Breast Neoplasms

NCT02675231 2024-11-26

monarcHER

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT06561022 2024-08-19

abemaSNF1/3

260 enrolled

Breast Neoplasms

NCT03703466 2024-04-02

A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

72 enrolled 19 charts

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

1 enrolled 5 charts

Breast Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

Breast Neoplasms

NCT02441946 2020-06-17

neoMONARCH

224 enrolled 20 charts

Breast Neoplasms

NCT02102490 2020-01-21

MONARCH 1

132 enrolled 17 charts 1 FDA